Case Study: Emerging Manufacturer achieves unified market access and faster patient insights with IntegriChain's ICyte platform

Tackling Rare Disease Using a Unified Market Access Platform

Emerging Manufacturer, preparing to launch a rare-disease therapy, faced limited internal expertise in gross-to-net and government pricing, lean operational capacity, siloed channel/payer/patient data, and a need for faster, more accurate insight into patient initiation, adherence, and specialty pharmacy performance. To address these challenges they engaged IntegriChain, implementing the ICyte platform along with Government Pricing Managed Service, Rebate Managed Service, Gross-to-Net Accruals Management, and Gross-to-Net Accruals Forecasting.

IntegriChain unified and refined channel, payer, and patient data on ICyte to create a single source of truth, enabling more accurate GTN accruals and forecasts, reconciled chargebacks, and faster “what‑if” scenario modeling that previously took weeks. The solution improved visibility into providers and patient programs, supported data-driven coaching of specialty pharmacies, reduced vendor sprawl and operational burden, and delivered measurable improvements in accrual accuracy, rebate/chargeback reconciliation, and the timeliness of access and commercialization decision-making.